| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8791270 | EAGLE PHARMS | Bendamustine pharmaceutical compositions |
Jan, 2026
(1 year, 8 months from now) | |
| US9572797 | EAGLE PHARMS | Formulations of bendamustine |
Jan, 2031
(6 years from now) | |
| US9265831 | EAGLE PHARMS | Formulations of bendamustine |
Jan, 2031
(6 years from now) | |
| US9572796 | EAGLE PHARMS | Formulations of bendamustine |
Jan, 2031
(6 years from now) | |
| US11844783 | EAGLE PHARMS | Formulations of bendamustine |
Jan, 2031
(6 years from now) | |
| US11103483 | EAGLE PHARMS | Formulations of bendamustine |
Jan, 2031
(6 years from now) | |
| US10010533 | EAGLE PHARMS | Formulations of bendamustine |
Jan, 2031
(6 years from now) | |
| US8609707 | EAGLE PHARMS | Formulations of bendamustine |
Aug, 2031
(7 years from now) | |
Belrapzo is owned by Eagle Pharms.
Belrapzo contains Bendamustine Hydrochloride.
Belrapzo has a total of 8 drug patents out of which 0 drug patents have expired.
Belrapzo was authorised for market use on 15 May, 2018.
Belrapzo is available in solution;intravenous dosage forms.
Belrapzo can be used as for the treatment of patients with indolent b-cell non-hodgkin lymphoma, for the treatment of patients with chronic lymphocytic leukemia.
The generics of Belrapzo are possible to be released after 11 August, 2031.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| ODE*(ODE*) | Dec 07, 2022 |
Drugs and Companies using BENDAMUSTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 15 May, 2018
Treatment: For the treatment of patients with indolent b-cell non-hodgkin lymphoma; For the treatment of patients with chronic lymphocytic leukemia
Dosage: SOLUTION;INTRAVENOUS
BELRAPZO family patents
